Evidence mapPaperPMID 36917413Full record

ArticleInternational urology and nephrology2023

Trends in mortality and comorbidities in hemodialysis patients between 2012 and 2017 in an East-European Country: a retrospective study.

Lazar Chisavu, Adelina Mihaescu, Flaviu Bob, Alexandru Motofelea, Oana Schiller, Luciana Marc, Razvan Dragota-Pascota, Flavia Chisavu, Adalbert Schiller

Full text read
In one paragraph

Article in International urology and nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Lazar ChisavuUniversity of Medicine and Pharmacy "Victor Babes" Timisoara, Timisoara, Romania.ORCID http://orcid.org/0000-0003-3664-1945
Adelina MihaescuUniversity of Medicine and Pharmacy "Victor Babes" Timisoara, Timisoara, Romania. mihaescu.adelina@umft.ro.ORCID http://orcid.org/0000-0002-3220-6623
Flaviu BobUniversity of Medicine and Pharmacy "Victor Babes" Timisoara, Timisoara, Romania.ORCID http://orcid.org/0000-0001-5082-3126
Alexandru MotofeleaUniversity of Medicine and Pharmacy "Victor Babes" Timisoara, Timisoara, Romania.ORCID https://orcid.org/0000-0003-4297-077X
Oana SchillerAvitum BBraun Dialysis Centre, Timisoara, Romania.
Luciana MarcUniversity of Medicine and Pharmacy "Victor Babes" Timisoara, Timisoara, Romania.
Razvan Dragota-PascotaUniversity of Medicine and Pharmacy "Victor Babes" Timisoara, Timisoara, Romania.
Flavia ChisavuUniversity of Medicine and Pharmacy "Victor Babes" Timisoara, Timisoara, Romania.ORCID http://orcid.org/0000-0001-9456-4517
Adalbert SchillerUniversity of Medicine and Pharmacy "Victor Babes" Timisoara, Timisoara, Romania.ORCID http://orcid.org/0000-0001-6843-7653

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to evidence trends and changes in mortality, comorbid conditions, prognosis, and causes of death after 5 years of continuous evolution of hemodialysis (HD) patients in Romania.

methodsWe included two cohorts of stable HD patients (901 from 2012 and 1396 from 2017). Both cohorts were followed up for 1 year. The 5-year survivors of the 2012 cohort were identified in 2017 and their data changes were assessed.

resultsThe 2017 patients were older, with longer time on dialysis, higher serum creatinine and urea levels, and required higher ultrafiltration volume per dialysis. They also had lower hemoglobin, lower C-reactive protein, higher albumin, higher calcium bicarbonate, and higher parathyroidectomy prevalence. The 2017 cohort presented with lower average dialysis flow, less administration of iron sucrose, had more catheters, lower hepatitis C prevalence, higher diabetes mellitus prevalence, higher heart valve calcifications, higher heart rate disorders, higher prevalence of left ventricular hypertrophy, and lower ejection fraction. Cardiovascular disease was the main cause of death in both years (50% in 2012 and 45.6% in 2017), followed by sepsis and cancer. The mortality was higher in 2017 compared to 2012 (14.1 vs 6.6%). The 5-year mortality was 37.2% with an average of 7.44%/year. The risk of death increased with age, higher C-reactive protein, higher phosphate, lower hemoglobin, and lower albumin.

conclusionCardiovascular disease remains the main causes of death in HD-treated patients but with decreasing trend. Developing regional therapeutic strategies for quality care with early intervention will most likely improve mortality.

Indexed as

Cardiovascular DiseasesKidney Failure, ChronicC-Reactive ProteinHumansRenal DialysisRetrospective StudiesC-Reactive ProteinCardiovascular deathCardiovascular diseaseComorbiditiesHemodialysisMortalitySurvival

Identifiers

PMID36917413
PMCPMC10012315

What Socratic holds

Textfull text, public
LicenceCC BY
reference markers read3
measurements read126
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.